Literature DB >> 2444242

Modulation of placental alkaline phosphatase activity and cytokeratins in human HN-1 cells by butyrate, retinoic acid, catecholamines and histamine.

J T Bijman1, D J Wagener, H van Rennes, J M Wessels, F C Ramaekers, P van den Broek.   

Abstract

The effects of butyrate and retinoic acid in combination with catecholamines or histamine on the HN-1 human head and neck squamous carcinoma cell line were investigated analysing cell proliferation, placental alkaline phosphatase (PLAP) activity, and relative cytokeratin content. Butyrate inhibited cell proliferation in agar, whereas retinoic acid induced a small inhibitory effect. Butyrate enhanced PLAP activity in a time related manner in contrast to retinoic acid, which had no significant effect. However, retinoic acid inhibited the efficacy of butyrate to induce PLAP activity. A synergistic enhancement of PLAP activity was demonstrated after treatment of butyrate pretreated cells with catecholamines or histamine. The beta-adrenergic antagonist propranolol partly inhibited the aforementioned enhancement of PLAP activity, whereas the alpha-adrenergic antagonist phentolamine further enhanced PLAP activity. Indirect labeling of keratins with a polyclonal antibody showed that cytokeratin content was enhanced by butyrate but not by retinoic acid. Further analysis of cytokeratin content using four monoclonal antibodies showed that labeling of cytokeratins (5 + 8) was increased by butyrate. PLAP activity could be modulated by a concerted action of either butyrate plus retinoic acid or butyrate plus catecholamines or histamine, indicating a possible role for PLAP in tumour cell proliferation.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2444242      PMCID: PMC2002146          DOI: 10.1038/bjc.1987.169

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  33 in total

1.  Relationship between beta-adrenergic receptors and adenylate cyclase in HeLa cells.

Authors:  R C Henneberry; C C Smith; J F Tallman
Journal:  Nature       Date:  1977-07-21       Impact factor: 49.962

2.  n-Butyrate causes histone modification in HeLa and Friend erythroleukaemia cells.

Authors:  M G Riggs; R G Whittaker; J R Neumann; V M Ingram
Journal:  Nature       Date:  1977-08-04       Impact factor: 49.962

3.  Differentiation of malignant to benign cells.

Authors:  G B Pierce; C Wallace
Journal:  Cancer Res       Date:  1971-02       Impact factor: 12.701

4.  Type of adrenoceptors involved in induction by adrenaline of hepatic alkaline phosphatase in mice in vivo.

Authors:  P L Mary; J P Rao
Journal:  Br J Pharmacol       Date:  1981-01       Impact factor: 8.739

Review 5.  Butyric acid: a small fatty acid with diverse biological functions.

Authors:  K N Prasad
Journal:  Life Sci       Date:  1980-10-13       Impact factor: 5.037

6.  Effect of sodium butyrate on chromatin structure.

Authors:  A Kitzis; L Tichonicky; N Defer; J Kruh
Journal:  Biochem Biophys Res Commun       Date:  1980-04-14       Impact factor: 3.575

7.  Induction of functional beta-adrenergic receptors in HeLa cells.

Authors:  J F Tallman; C C Smith; R C Henneberry
Journal:  Proc Natl Acad Sci U S A       Date:  1977-03       Impact factor: 11.205

8.  Neural control of colonic cell proliferation.

Authors:  P J Tutton; D H Barkla
Journal:  Cancer       Date:  1980-03-15       Impact factor: 6.860

9.  Ten human carcinoma cell lines derived from squamous carcinomas of the head and neck.

Authors:  D M Easty; G C Easty; R L Carter; P Monaghan; L J Butler
Journal:  Br J Cancer       Date:  1981-06       Impact factor: 7.640

10.  Adrenergic factors regulating cell division in the colonic crypt epithelium during carcinogenesis and in colonic adenoma and adenocarcinoma.

Authors:  M F Kennedy; P J Tutton; D H Barkla
Journal:  Br J Cancer       Date:  1985-09       Impact factor: 7.640

View more
  1 in total

1.  Repurposing Drugs in Oncology (ReDO)-Propranolol as an anti-cancer agent.

Authors:  Pan Pantziarka; Gauthier Bouche; Vidula Sukhatme; Lydie Meheus; Ilse Rooman; Vikas P Sukhatme
Journal:  Ecancermedicalscience       Date:  2016-10-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.